BLPH Key Statistics, Chart & Performance
The current stock price of BLPH is 0.1025 USD. In the past month the price decreased by -75.43%. In the past year, price decreased by -90.05%.
BLPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.68 | 395.45B | ||
| AMGN | AMGEN INC | 15.09 | 177.66B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.96 | 118.73B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.19 | 81.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 795.31 | 53.59B | ||
| INSM | INSMED INC | N/A | 37.27B | ||
| NTRA | NATERA INC | N/A | 34.14B | ||
| BIIB | BIOGEN INC | 10.9 | 26.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.08 | 21.68B | ||
| INCY | INCYTE CORP | 16.6 | 20.92B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About BLPH
Company Profile
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. The company is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
Company Info
BELLEROPHON THERAPEUTICS INC
184 Liberty Corner Road, Suite 302
WARREN NEW JERSEY 07059 US
CEO: Fabian Tenenbaum
Employees: 18
Phone: 19085744770.0
BELLEROPHON THERAPEUTICS INC / BLPH FAQ
What does BELLEROPHON THERAPEUTICS INC do?
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. The company is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.
Can you provide the latest stock price for BELLEROPHON THERAPEUTICS INC?
The current stock price of BLPH is 0.1025 USD. The price decreased by -73.39% in the last trading session.
Does BELLEROPHON THERAPEUTICS INC pay dividends?
BLPH does not pay a dividend.
How is the ChartMill rating for BELLEROPHON THERAPEUTICS INC?
BLPH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting BLPH stock to perform?
6 analysts have analysed BLPH and the average price target is 2.04 USD. This implies a price increase of 1890.24% is expected in the next year compared to the current price of 0.1025.
What sector and industry does BELLEROPHON THERAPEUTICS INC belong to?
BELLEROPHON THERAPEUTICS INC (BLPH) operates in the Health Care sector and the Biotechnology industry.
BLPH Technical Analysis
BLPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BLPH. The financial health of BLPH is average, but there are quite some concerns on its profitability.
BLPH Financial Highlights
Over the last trailing twelve months BLPH reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 38.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -110.28% | ||
| ROE | -220.54% | ||
| Debt/Equity | 0 |
BLPH Forecast & Estimates
6 analysts have analysed BLPH and the average price target is 2.04 USD. This implies a price increase of 1890.24% is expected in the next year compared to the current price of 0.1025.